Webinar | February 21, 2024

Immunogenicity - Challenge For Protein Drugs

Source: ATUM

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response. Explore research on the immunogenicity of high-risk biotherapeutics, explaining how anti-drug antibodies (ADA) can lead to safety and efficacy issues. Factors influencing immunogenicity risk are broken down into product-associated, disease biology-associated, and patient-associated. The concept of "humanness" in biotherapeutics and the role of T cell and B cell epitopes, biophysical properties, post-translational modifications, pharmacokinetics, and immune modulation are discussed. The presentation also covers techniques such as germlining to increase signal content and improve tolerance, with a study showing a significant reduction in ADA through germline mutations.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online